Making the discoveries that defeat cancer

  • Home »
  • Research »
  • Repository

  • Administrators Login

  • Repository Homepage
  • About the Repository
  • Browse the Repository
  • Search the Repository
  • Contribute an Article
  • Missing Publications
  • Repository Help

A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI((TM))), in patients with advanced solid tumours

Tools
- Tools
+ Tools

Scott, E. N., Thomas, A. L., Molife, L. R., Ahmed, S., Blagden, S., Fong, P. C., Kowal, K., McCoy, C., Wiesinger, H., Steward, W., De Bono, J. (2009) A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI((TM))), in patients with advanced solid tumours. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 64 (2). pp. 425-429. ISSN 0344-5704

Full text not available from this repository.

Abstract

The toxicities, pharmacokinetics and recommended dose of oral once daily ZK 304709, a novel multi-targeted growth inhibitor (MTGI((TM))) with activity against cell-cycle progression and angiogenesis, was investigated in patients by administration for 14 consecutive days followed by 14 days recovery. Patients with solid tumours resistant to standard treatments were enrolled in an accelerated titration design. Thirty-seven patients received ZK 304709 from 15 to 285 mg daily. The most common drug-related adverse events were vomiting, diarrhoea and fatigue. Systemic exposure to ZK 304709 increased with dose up to 90 mg daily but plateaued thereafter, with high inter-individual variability at all doses. Thirteen patients had stable disease as best response as per RECIST criteria. There was no increase in exposure to ZK 304709 with dose escalation above 90 mg, and the MTD was not determined. This study illustrates the importance of phase I pharmacokinetic data to guide dose escalation and drug development.

Item Type: Article
Authors (ICR Faculty only): De-Bono, Johann
All Authors: Scott, E. N., Thomas, A. L., Molife, L. R., Ahmed, S., Blagden, S., Fong, P. C., Kowal, K., McCoy, C., Wiesinger, H., Steward, W., De Bono, J.
Uncontrolled Keywords: Antiangiogenesis; Cyclin-dependent kinase inhibitor; Phase I trial; ZK 304709 CANCER
Research teams: ICR divisions > Cancer Therapeutics > Cancer Biomarkers
ICR divisions > Clinical Studies > Cancer Biomarkers

ICR divisions > Clinical Studies > Prostate Cancer Targeted Therapy Group
Depositing User: Users 10 not found.
Date Deposited: 29 Jun 2009 10:07
Last Modified: 11 Jul 2017 09:58
URI: http://publications.icr.ac.uk/id/eprint/8272

Actions (login required)

View Item View Item
The Royal Marsden - NHS foundation trust